ORPHAZYME
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
ORPHAZYME
Industry:
Biotechnology Genetics Health Diagnostics Therapeutics
Founded:
2009-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.orphazyme.com
Total Employee:
51+
Status:
Active
Contact:
45 70 70 29 80
Email Addresses:
[email protected]
Total Funding:
263.34 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Denali Therapeutics
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Coave Therapeutics
Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
Oxford BioMedica
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Kurma Partners
Kurma Partners investment in Post-IPO Equity - Orphazyme
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Post-IPO Equity - Orphazyme
Life Sciences Partners
Life Sciences Partners investment in Post-IPO Equity - Orphazyme
Idinvest Partners
Idinvest Partners investment in Post-IPO Equity - Orphazyme
Novo Holdings
Novo Holdings investment in Post-IPO Equity - Orphazyme
Aescap Venture
Aescap Venture investment in Post-IPO Equity - Orphazyme
ALS Investment Fund
ALS Investment Fund investment in Venture Round - Orphazyme
Kurma Partners
Kurma Partners investment in Venture Round - Orphazyme
Aescap Venture
Aescap Venture investment in Venture Round - Orphazyme
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Venture Round - Orphazyme
Official Site Inspections
http://www.orphazyme.com Semrush global rank: 4.16 M Semrush visits lastest month: 2.85 K
- Host name: joel.biz
- IP address: 188.166.160.142
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "Orphazyme"
Orphazyme - Crunchbase Company Profile & Funding
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the …See details»
Annual report - orphazyme.com
We significantly scaled back our global organization, including teams based in the U.S. and Europe, with the purpose of reducing the number of employees to those ... May 30, 2022 by …See details»
Changes to the Board of Directors - Yahoo Finance
May 23, 2022 Orphazyme A/S in restructuringCompany announcement No. 27/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, May 23, …See details»
Orphazyme Company Profile - Office Locations, Competitors
Oct 1, 2024 Orphazyme develops therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases. The Company focuses on development of cell …See details»
Orphazyme Announces Publication of 2022 Financial Results and …
Company announcement Orphazyme A/S No. 02/2023 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme Announces …See details»
News - Orphazyme
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm May 31, 2022. With reference to company announcement no. 24/2022 dated May 15, 2022, …See details»
Orphazyme - EQT Group
Latest news. 24 September 2024 EQT Active Core Infrastructure fund holds final close; 24 September 2024 EQT Welcomes Sixth Street as Strategic Investor in EdgeConneXSee details»
Orphazyme Announces Publication of 2021 Financial ... - Yahoo …
Jun 7, 2022 Orphazyme A/SCompany announcementNo. 30/2022 Annual reportwww.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, …See details»
Orphazyme provides regulatory update from FDA on arimoclomol …
Jun 18, 2021 Orphazyme A/SCompany announcement No. 16/2021Inside informationCompany Registration No. 32266355 Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; …See details»
Changes to the Executive Management of Orphazyme – Anders
Jan 31, 2022 Orphazyme A/SCompany announcementNo. 03/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, …See details»
Orphazyme reports business highlights and financial results in …
Orphazyme A/S Company announcement ... DKK 214.2 million compared to DKK 78.6 million for the same period in 2020 due to the build-up of the commercial organization in preparation for …See details»
Orphazyme files for US IPO, global offering to advance …
Sep 4, 2020 Orphazyme A/S filed for an IPO to list American depositary shares on the Nasdaq Global Market under the ticker symbol ORPH as part of a global offering of its ordinary …See details»
Orphazyme announces presentation of 2020 Annual Report
Feb 23, 2021 Copenhagen, Denmark and Chicago, IL, USA, February 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company …See details»
After Orphazyme's pipeline in a product bursts, the inevitable tide ...
Jun 29, 2021 As part of the restructuring, Orphazyme will “significantly scale back its global organization, including teams based in the U.S. and Europe, with the purpose of reducing the …See details»
Orphazyme announces restructuring to focus resources on …
Orphazyme A/S Company announcement No. 20/2021 Inside information Company Registration No. 32266355 -Significant headcount reduction of global workforce to free resources- …See details»
Orphazyme reports financial results in Interim Report First Half 2022
Sep 26, 2022 Company announcementOrphazyme A/SNo. 36/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, …See details»
Orphazyme establishes U.S. headquarters in Chicago as the
Dec 2, 2020 Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA). About arimoclomol Arimoclomol is an investigational drug candidate that amplifies …See details»
Orphazyme establishes U.S. headquarters in Chicago as the …
Orphazyme A/S. Chicago: Molly Carey Poarch +1- 312-288-9721. Copenhagen: Anders Vadsholt, CFO +45 28 98 90 55 . About Orphazyme A/S Orphazyme is a late-stage biopharmaceutical …See details»
Orphazyme completes sale of substantially all of its assets
May 31, 2022 Following completion of the Sale of Assets to KemPharm, Orphazyme will no longer have any material ongoing operational business activities and KemPharm will retain all …See details»
Orphazyme on last leg as court-mediated restructuring drives …
Mar 10, 2022 In late March 2021, Orphazyme announced its lead asset, arimoclomol, failed to improve disease progression in a phase 2/3 trial for inclusion body myositis, a progressive …See details»